-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Jcc3eNZaSlNJRSi692kndlbx9kagKZCyWBcfwiQbfmDEzwDtgIecnPI9Z1jnDKvZ 1lnkVIq7vWTyIPmSHM/lMA== 0001179110-08-000150.txt : 20080102 0001179110-08-000150.hdr.sgml : 20080101 20080102183027 ACCESSION NUMBER: 0001179110-08-000150 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20071228 FILED AS OF DATE: 20080102 DATE AS OF CHANGE: 20080102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NATROL INC CENTRAL INDEX KEY: 0001025573 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 953560780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21411 PRAIRIE ST CITY: CHATSWORTH STATE: CA ZIP: 91311 BUSINESS PHONE: 8187396000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simon Ralph CENTRAL INDEX KEY: 0001365166 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24567 FILM NUMBER: 08503234 BUSINESS ADDRESS: BUSINESS PHONE: 011-44-787-617-6063 MAIL ADDRESS: STREET 1: 21411 PRAIRIE ST. CITY: CHATSWORTH STATE: CA ZIP: 91311 4 1 edgar.xml FORM 4 - X0202 4 2007-12-28 1 0001025573 NATROL INC NTOL 0001365166 Simon Ralph NATROL, INC. 21411 PRAIRIE ST. CHATSWORTH CA 91311 1 0 0 0 Stock Option (Right to Buy) 2.50 2007-12-28 4 D 0 158333 1.90 D 2016-04-28 Common Stock 158333 0 D Pursuant to an Agreement and Plan of Merger, dated as of November 18, 2007 (the "Merger Agreement"), by and among the Issuer, Plethico Pharmaceuticals Limited ("Parent"), and Nutra Acquisition Company, Inc. (Merger Sub), immediately prior to the Effective Time (as defined in the Merger Agreement), each outstanding option to purchase shares of common stock of the Issuer, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash in respect thereof equal to the product of (i) the excess, if any, of the Offer Price (i.e., $4.40 per share) over the exercise price thereof (i.e., $2.50 per share) and (ii) the number of shares of common stock of the Issuer subject thereto (158,333), without interest thereon. By: Loida C. Rubio, Attorney-in-Fact 2008-01-02 -----END PRIVACY-ENHANCED MESSAGE-----